SynthesisSystematic reviews2022

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.

Ye Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.